Intratumoral anti-CTLA-4 therapy: Enhancing efficacy while avoiding toxicity

Aurelien Marabelle, Holbrook Kohrt, Ronald Levy

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)

Abstract

Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.

Original languageEnglish
Pages (from-to)5261-5263
Number of pages3
JournalClinical Cancer Research
Volume19
Issue number19
DOIs
Publication statusPublished - 1 Oct 2013
Externally publishedYes

Cite this